[Open clinical trial of a new oral galenic form of ketoprofen].
Thirty-two patients with rheumatoid arthritis and several other rheumatic diseases were entered into a randomized study to investigate the correlation between the pharmacokinetics and clinical effectiveness of Bi-Profenid 150 mg. Each patient was given, in a variable order, one 150 mg Bi-Profenid tablet twice daily for 2 days, and two 50 mg Profenid capsules each morning and noon with one 100 mg suppository each evening for 2 days. Dosage convenience, effectiveness on pain during the second part of the night and resolution of morning stiffness were considered better with Bi-Profenid by 23 patients and with conventional forms by four, while five reported no preference. In 15 patients treated for one month, only 5 reported mild side-effects which did not require withdrawal from the study. The patients' preference appears to be a result of the bioavailability of Bi-Profenid.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002214:Capsules; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage*; D013607:Tablets
D002214:Capsules; D003692:Delayed-Action Preparations; D010666:Phenylpropionates; D013607:Tablets; D007660:Ketoprofen
Expérimentation clinique en essai ouvert d'une nouvelle forme galénique orale du kétoprofène.